OncoSynergy, Inc. Report issue

For profit Phase 1
Founded: Stamford CT United States (2011)

Organization Overview

First Clinical Trial
2020
NCT04608812
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

OncoSynergy, Inc.

Active Ingredients

Drugs in Phase 1 Trials (2)

gadoteridol (prohance) (1 trial)

os2966 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 1)

Glioblastoma (Phase 1)

Glioma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2